Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease

NCT01951326 is registered in ClinicalTrials.gov with RedHill Biopharma Limited as lead sponsor.

NCT NCT01951326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01951326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
Lead sponsor
RedHill Biopharma Limited
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2013
Completion date
August 31, 2019
Enrollment
331 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease